-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, Shiyao Group (01093.HK) announced that a pioneering PD-1/IL-15 bispecific fusion protein SYS6090 (JMT108) (this product) has been granted fast-track status by the US Food and Drug Administration (FDA) to treat patients with microsatellite-stabilized (MSS) or complete mismatch repair (mCRC) disease progression after previous standard systematic treatment.

Zhitongcaijing·08/26/2026 10:17:10
Listen to the news
Zhitong Financial App News, Shiyao Group (01093.HK) announced that a pioneering PD-1/IL-15 bispecific fusion protein SYS6090 (JMT108) (this product) has been granted fast-track status by the US Food and Drug Administration (FDA) to treat patients with microsatellite-stabilized (MSS) or complete mismatch repair (mCRC) disease progression after previous standard systematic treatment.